Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2057MR)

This product GTTS-WQ2057MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets Canlupfam PDCD1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001314097.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 486213
UniProt ID A0A090BAM7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2057MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12627MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ7025MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Fab C225
GTTS-WQ5739MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ6268MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ4181MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ14785MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-40
GTTS-WQ463MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 3G3
GTTS-WQ273MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 17-1A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW